On the face of it, the battle between Amgen and Sanofi/Regeneron being heard in the US Supreme Court is a mundane biopharma contest over rights and royalties on PCSK9 inhi
Roche is on course for a third indication for its fast-growing ophthalmic disease therapy Vabysmo, after a pair of phase 3 trials showed it was effective at improving eyes
